Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.000.17%
QQQ
714.250.11%
BTC/USD
76328.990.9415%
DIA
532.330.02%
GLD
423.090.06%
TLT
82.020.04%

Actuate Therapeutics Inc

ACTUNASDAQ
Trade with Public
Trade with Public
$1.27
0.043.25%
At close: Aug 21, 5:00 PM EST
$1.29
0.021.57%
After Hours: Aug 21, 6:34 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Actuate Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Actuate Therapeutics (ACTU).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$14Upside to Avg. PT+959.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026HC Wainwright & Co.Swayampakula RamakanthMaintainedBuy$15
Jul 30, 2026Rodman & RenshawMichael G. King Jr.InitiateBuy$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
Benzinga Newsdesk

This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Avi Kapoor

PRO
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Actuate Therapeutics (NASDAQ:ACTU) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.
Benzinga Newsdesk

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved